IP Library Granted Patent US 7,262,024
Granted Patent B2
US 7,262,024 · App. 10/324,143 · Granted Aug 28, 2007

Patent

Assignee: ID Biomedical Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,262,024
App. No.
10/324,143
Granted
Aug 28, 2007
Kind
B2
Abstract

The present invention relates to polypeptides of Streptococcus pneumoniae which may be used for prophylaxis, diagnostic and/or therapy purposes.

Claims (12)

1. An isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:3, or the complement of the full-length polynucleotide sequence.

2. An isolated polynucleotide comprising a polynucleotide sequence at least 95% identical to the polynucleotide sequence set forth in SEQ ID NO:6, or the complement of the frill-length polynucleotide sequence, wherein the polynucleotide encodes a polypeptide that elicits an immune response to Streptococcus in an individual and that is capable of eliciting an antibody that specifically binds to the polypeptide comprising the amino acid sequence set forth in SEQ ID NO:3.

3. The isolated polynucleotide according to claim 2 comprising a polynucleotide sequence at least 97% identical to the polynucleotide sequence set forth in SEQ ID NO:6, or the complement of the full-length polynucleotide sequence.

4. The polynucleotide according to claim 2 comprising the polynucleotide sequence set forth in SEQ ID NO:6, or the complement of the full-length polynucleotide sequence.

5. The polynucleotide according to any one of claims 1 - 4 wherein the polynucleotide is DNA.

6. The polynucleotide according to any one of claims 1 - 4 wherein the polynucleotide is RNA.

7. A vector comprising the polynucleotide of any one of claims 1 - 4 , wherein the polynucleotide is operably linked to an expression control region.

8. A host cell comprising the vector according to claim 7 .

9. A process for producing a polypeptide, said process comprising culturing a host cell according to claim 8 under conditions suitable for expression of the polypeptide.

10. The process according to claim 9 , further comprising isolating the expressed polypeptide.

11. The isolated polynucleotide according to claim 2 wherein the Streptococcus is Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae , or Streptococcus uberis.

12. The isolated polynucleotide according to claim 2 wherein the Streptococcus is Streptococcus pneumoniae.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2004
From: SHIRE BIOCHEM INC. (FORMERLY BIOCHEM PHARMA INC.; BIOCHEM VACCINES INC.; IAF BIO VAC INC.
To: ID BIOMEDICAL CORPORATION
Reel/Frame 016076/0358 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2003
From: HAMEL, JOSEE; CHARLAND, NATHALIE; BRODEUR, BERNARD R.; MARTIN, DENIS; BLAIS, NORMAND; OUELLET, CATHERINE; LABBE, STEVE
To: SHIRE BIOCHEM INC.
Reel/Frame 014140/0371 →
Continuity (2)
Provisional Application 6034125200 · Dec 20, 2001
Related Publication 20030232976A1 · Dec 18, 2003